+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Peptide Market Strategic Intelligence Suite 2026-2031

  • PDF Icon

    Report

  • 551 Pages
  • April 2026
  • Region: Global
  • Navadhi
  • ID: 6286022
Description Jump to:
The Global Peptide Market Strategic Intelligence Suite 2026-2031 is Navadhi Market Research's most comprehensive intelligence offering on the global peptide industry, combining the Peptide Therapy, Peptide API, and Cosmetic Peptides reports (a combined USD 90.3 billion in 2025, growing to over USD 206 billion by 2031) plus a cross-report executive presentation, summary document, and interactive infographic.

The three reports cover sequential and parallel stages of the peptide value chain: Peptide API covers the raw active ingredient manufacturing (USD 5.15B to USD 12.1B, 15.24% CAGR), which feeds into both Peptide Therapy's finished drug products (USD 84.2B to USD 192.1B, 14.74% CAGR, dominated by the GLP-1 revolution) and Cosmetic Peptides' topical formulations (USD 0.95B to USD 2.1B, 13.84% CAGR).

The GLP-1/GIP Receptor Agonist Therapy segment is the single most important structural driver across the suite, accounting for 65.8% of therapy-market value and nearly half of all peptide API revenue by 2031, led by the Novo Nordisk/Eli Lilly duopoly.

Scope of Global Peptide Market Strategic Intelligence Suite 2026-2031

  • This Suite includes the complete Global Peptide Therapy Market Strategic Research Report.
  • This Suite includes the complete Global Peptide API Market Strategic Research Report.
  • This Suite includes the complete Global Cosmetic Peptides Market Strategic Research Report.
  • This Suite includes an executive presentation comparing all three reports' key findings.
  • This Suite includes a cross-report summary document explaining the peptide value-chain linkage.
  • This Suite includes an interactive infographic for board-level and investor-facing use.

Who can use the Global Peptide Market Strategic Intelligence Suite?

This Suite is ideal for people who need the complete peptide value chain in one integrated resource. Some of the intended users are:

  • Investors evaluating full value-chain exposure across peptide therapeutics, API manufacturing, and cosmetics
  • Supply chain executives assessing peptide API capacity and sourcing risk
  • C-level executives requiring comprehensive peptide strategic intelligence for board presentations.

Table of Contents

Global Peptide Market Strategic Intelligence Suite Table of Contents
Global Peptide Market Strategic Intelligence Suite Suite Overview
Suite Introduction: The Global Peptide Value Chain 2026-2031
How the Three Reports Interconnect
Suite Bonus Deliverables: Presentation, Summary Document and Infographic
Report 1: Global Peptide Therapy Market Strategic Research Report 2026-2031
Publication ID: NAV0426005 | 161 Pages | April 22, 2026
1. Executive Summary
Scope of Global Peptide Therapy Market Strategic Research Report 2026-2031 Research Methodology
2. Forecast for Global Peptide Therapy Market 2026-2031
2.1 Overall Global Peptide Therapy Market Forecast 2026-2031 by Value (in USD billion)
2.2 Overall Global Peptide Therapy Market Forecast 2026-2031 by Volume (in Billion Dosage Units)
3. Segment by Type Market Share in Global Peptide Therapy Market 2026-2031
3.1 Global GLP-1/GIP Receptor Agonist Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.2 Global Somatostatin Analog Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.3 Global LHRH Analog / GnRH Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.4 Global Hormonal Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.5 Global Immunomodulatory Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.6 Global Bone & Growth Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.7 Global Oncology Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
3.8 Global Other Peptide Therapies Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4. Segment by Application Market Share in Global Peptide Therapy Market 2026-2031
4.1 Global Diabetes & Obesity Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.2 Global Oncology (Cancer Treatment) Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.3 Global Endocrinology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.4 Global Reproductive Health & Urology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.5 Global Immunology & Transplant Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.6 Global Bone Metabolism & Mineral Disorders Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.7 Global Rare Diseases & Orphan Conditions Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
4.8 Global Other Applications Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
5. Region-Wise Market Share in Global Peptide Therapy Market 2026-2031
5.1 Asia-Pacific Peptide Therapy Market Value and Volume Forecast 2026-2031
— China · Japan · India · South Korea · Australia · Rest of Asia Pacific
5.2 North America Peptide Therapy Market Value and Volume Forecast 2026-2031
— USA · Canada
5.3 Europe Peptide Therapy Market Value and Volume Forecast 2026-2031
— Germany · France · United Kingdom · Italy · Spain · Rest of Europe
5.4 Middle East & Africa Peptide Therapy Market Value and Volume Forecast 2026-2031
— Saudi Arabia · UAE · Israel · South Africa · Turkey · Rest of Middle East & Africa
5.5 Latin America Peptide Therapy Market Value and Volume Forecast 2026-2031
— Brazil · Mexico · Argentina · Colombia · Rest of Latin America
5.6 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
6. Key Growth Drivers for Global Peptide Therapy Market
6.1 GLP-1 Global Obesity Epidemic & Disease Burden
6.2 Regulatory Milestone Cascade Creating New Market Segments
6.3 PRRT and Radioligand Peptide Oncology Expansion
6.4 Next-Generation Peptide Drug Innovation Pipeline
6.5 GLP-1 Biosimilar Volume Expansion in Emerging Markets
6.6 AI-Driven Peptide Drug Discovery Accelerating Pipeline
7. Key Pain Areas / Growth Inhibitors for Global Peptide Therapy Market
7.1 Affordability & Insurance Coverage Gaps
7.2 API Supply Constraints and Manufacturing Complexity
7.3 Long-Term Safety, Durability & Weight Regain Concerns
7.4 Patent Litigation and Biosimilar Market Entry Complexity
7.5 Geopolitical Risk: BIOSECURE Act and Chinese API Dependency
7.6 Market Concentration Risk - Two-Company Duopoly
8. Key Players in Global Peptide Therapy - Competitive Landscape and SWOT Analysis
8.1 Novo Nordisk A/S — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.2 Eli Lilly and Company — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.3 Novartis AG — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.4 Ipsen SA — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.5 AbbVie Inc. — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.6 Teva Pharmaceutical Industries — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.7 AstraZeneca plc — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.8 Ferring Pharmaceuticals — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.9 Pfizer Inc. — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
8.10 Amgen Inc. — Revenue, Volume, ASP and Gross Margin (2020-2025E) + SWOT Analysis
9. Competitive Landscape of Key Players in the Global Peptide Therapy Market
9.1 Revenue Comparison 2020-2025E (Peptide Therapy Drug Sales, USD Million)
9.2 Revenue Growth Analysis: Winners & Laggards
9.3 Product Coverage Matrix
9.4 Geographic Coverage Matrix
9.5 Strategic Capability Benchmarking
9.6 Head-to-Head: Novo Nordisk vs. Eli Lilly — The GLP-1 Duopoly Battle
9.7 Strategic Positioning Framework
9.8 M&A Activity, Partnerships & Strategic Moves (2023-2026)
9.9 Competitive Summary Scorecard
10. Porter's Five Forces Analysis of Global Peptide Therapy Market
10.1 Bargaining Power of Suppliers: Low-Medium
10.2 Bargaining Power of Buyers: Medium-High
10.3 Threat of New Entrants: Low
10.4 Threat of Substitution: Low-Medium
10.5 Intensity of Competitive Rivalry: Medium-High
11. PESTLE Analysis of Global Peptide Therapy Market
11.1 Political (P) · 11.2 Economic (E) · 11.3 Social (S) · 11.4 Technological (T) · 11.5 Legal (L) · 11.6 Environmental (E)
12. SWOT Analysis of Global Peptide Therapy Market
13. Future Trends in Global Peptide Therapy Market
Report 2: Global Peptide API Market Strategic Research Report 2026-2031
Publication ID: NAV0426003 | 201 Pages | April 22, 2026
1. Executive Summary
Scope of Global Peptide API Market Strategic Research Report 2026-2031 Research Methodology
2. Forecast for Global Peptide API Market 2026-2031
2.1 Overall Global Peptide API Market Forecast 2026-2031 by Value (in USD billion)
2.2 Overall Global Peptide API Market Forecast 2026-2031 by Volume (in metric tonnes (MT))
3. Segment by Type Market Share in Global Peptide API Market 2026-2031
3.1 Global GLP-1 Receptor Agonist API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.2 Global Hormonal Peptide API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.3 Global Oncology Peptide API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.4 Global Antimicrobial Peptide API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.5 Global CNS/Neuropeptide API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.6 Global Cardiovascular Peptide API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.7 Global Immunology/Rare Disease API Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.8 Global Research, Cosmetics & Other Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4. Segment by Application Market Share in Global Peptide API Market 2026-2031
4.1 Global Diabetes & Obesity (GLP-1/GIP) Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.2 Global Oncology Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.3 Global Rare Diseases (Orphan Drugs) Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.4 Global Cardiovascular Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.5 Global Infectious Diseases/Antimicrobial Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.6 Global CNS/Neurology Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.7 Global Reproductive Health/Hormonal Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.8 Global Research, Diagnostics & Other Market Value (USD billion) and Volume (metric tonnes (MT)) Forecast 2026-2031
5. Region-Wise Market Share in Global Peptide API Market 2026-2031
5.1 Asia-Pacific Peptide API Market Value and Volume Forecast 2026-2031
— China · India · Japan · South Korea · Taiwan · Rest of Asia Pacific
5.2 North America Peptide API Market Value and Volume Forecast 2026-2031
— USA · Canada · Rest of North America
5.3 Europe Peptide API Market Value and Volume Forecast 2026-2031
— Switzerland · Germany · France · Belgium · United Kingdom · Ireland · Rest of Europe
5.4 Middle East & Africa Peptide API Market Value and Volume Forecast 2026-2031
— Israel · UAE · Saudi Arabia · South Africa · Rest of Middle East & Africa
5.5 Latin America Peptide API Market Value and Volume Forecast 2026-2031
— Brazil · Mexico · Argentina · Rest of Latin America
5.6 Top 15 Countries in Peptide API Market by 2031 Value (in USD billion)
6. Key Growth Drivers for Global Peptide API Market
6.1 GLP-1 Blockbuster Drugs Demand Surge
6.2 Massive CDMO Capacity Investment
6.3 Expanding Peptide Pipeline Beyond GLP-1
6.4 Increasing Pharma Outsourcing to CDMOs
6.5 GLP-1 Price Decline Democratising Access
6.6 Oral Peptide Technology Advancement
7. Key Pain Areas / Growth Inhibitors for Global Peptide API Market
7.1 SPPS Solvent Waste and Sustainability Pressure
7.2 Manufacturing Capacity Lag vs. Demand Surge
7.3 Geopolitical Risk in Chinese API Supply
7.4 Complex Chemistry Scaling Challenges
7.5 High Capital Intensity Creating Barriers and Concentration Risk
7.6 Regulatory Complexity and Variability
8. Key Players in Global Peptide API - Competitive Landscape and SWOT Analysis
8.1 Bachem (Julius Bachem AG) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.2 PolyPeptide Group — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.3 CordenPharma International — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.4 WuXi STA (WuXi AppTec Peptide) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.5 Hybio Pharmaceutical — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.6 AmbioPharm Inc. — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.7 ScinoPharm Taiwan — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.8 Almac Group (Almac Sciences) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.9 Piramal Pharma Solutions — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.10 CPC Scientific Inc. — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.11 GL Biochem (Shanghai) Ltd. — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
9. Competitive Landscape of Key Players in the Global Peptide API Market
9.1 Three-Tier Competitive Architecture
9.2 Revenue Comparison & Market Share 2020-2031
9.3 Gross Margin Comparison (2020-2025E)
9.4 Revenue Growth Analysis — Winners & Laggards
9.5 Product Coverage Matrix
9.6 Geographic Coverage Matrix
9.7 Strategic Capability Benchmarking
9.8 Head-to-Head Competitive Comparisons
— Bachem Group vs. PolyPeptide Group — Premium Swiss CDMO Rivalry
— CordenPharma International vs. WuXi STA — Capacity Race for GLP-1 API Scale
— Hybio Pharmaceutical vs. ScinoPharm Taiwan — Asian Listed Peptide Specialists
9.9 M&A Activity, Partnerships & Strategic Moves
9.10 Strategic Positioning Framework
9.11 Competitive Summary Scorecard
10. Porter's Five Forces Analysis of Global Peptide API Market
10.1 Bargaining Power of Suppliers: Low
10.2 Bargaining Power of Buyers: High
10.3 Threat of New Entrants: Low-Medium
10.4 Threat of Substitution: Low
10.5 Intensity of Competitive Rivalry: High
11. PESTLE Analysis of Global Peptide API Market
11.1 Political (P) · 11.2 Economic (E) · 11.3 Social (S) · 11.4 Technological (T) · 11.5 Legal (L) · 11.6 Environmental (E)
12. SWOT Analysis of Global Peptide API Market
13. Future Trends in Global Peptide API Market
Report 3: Global Cosmetic Peptides Market Strategic Research Report 2026-2031
Publication ID: NAV0426004 | 168 Pages | April 22, 2026
1. Executive Summary
Scope of Global Cosmetic Peptides Market Strategic Research Report 2026-2031 Research Methodology
2. Forecast for Global Cosmetic Peptides Market 2026-2031
2.1 Overall Global Cosmetic Peptides Market Forecast 2026-2031 by Value (in USD million)
2.2 Overall Global Cosmetic Peptides Market Forecast 2026-2031 by Volume (in metric tonnes (MT))
3. Segment by Type Market Share in Global Cosmetic Peptides Market 2026-2031
3.1 Global Signal Peptides (Matrixyl, Palmitoyl) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.2 Global Neurotransmitter Inhibitor Peptides (Argireline) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.3 Global Carrier Peptides (GHK-Cu, Enzyme Cofactors) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.4 Global Enzyme Inhibitor Peptides (Leuphasyl, Syn-Ake) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.5 Global Bioidentical Peptides & Mimetics Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.6 Global Structural/Tensor Peptides (Snap-8, BONT) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
3.7 Global Other Cosmetic Peptides Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4. Segment by Application Market Share in Global Cosmetic Peptides Market 2026-2031
4.1 Global Anti-Aging & Wrinkle Reduction Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.2 Global Skin Brightening & Hyperpigmentation Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.3 Global Moisturization & Barrier Repair Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.4 Global Hair Growth & Scalp Care Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.5 Global Firming & Body Contouring Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.6 Global Eye Care & Lip Plumping Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
4.7 Global Color Cosmetics (Peptide Primers) Market Value (USD million) and Volume (metric tonnes (MT)) Forecast 2026-2031
5. Region-Wise Market Share in Global Cosmetic Peptides Market 2026-2031
5.1 Asia-Pacific Cosmetic Peptides Market Value and Volume Forecast 2026-2031
— China · Japan · South Korea · India · Australia · Rest of Asia Pacific
5.2 North America Cosmetic Peptides Market Value and Volume Forecast 2026-2031
— USA · Canada
5.3 Europe Cosmetic Peptides Market Value and Volume Forecast 2026-2031
— Germany · France · United Kingdom · Italy · Spain · Rest of Europe
5.4 Middle East & Africa Cosmetic Peptides Market Value and Volume Forecast 2026-2031
— UAE · Saudi Arabia · South Africa · Rest of Middle East & Africa
5.5 Latin America Cosmetic Peptides Market Value and Volume Forecast 2026-2031
— Brazil · Mexico · Colombia · Argentina · Rest of Latin America
5.6 Top 15 Countries in Cosmetic Peptides Market by 2031 Value (in USD million)
6. Key Growth Drivers for Global Cosmetic Peptides Market
6.1 Aging Population & 'Pre-Juvenation' Trend
6.2 K-Beauty & C-Beauty Globalisation
6.3 TikTok Ingredient Literacy & Science-Backed Beauty
6.4 Biotechnology Wave in Cosmetic Active Development
6.5 'Skinification' of Hair, Body & Colour Cosmetics
6.6 AI-Personalised Beauty Driving Multi-Peptide Combinations
7. Key Pain Areas / Growth Inhibitors for Global Cosmetic Peptides Market
7.1 Clinical Evidence Gap & Ingredient Efficacy Scrutiny
7.2 Chinese Commodity Supplier Competition & Price Erosion
7.3 Regulatory Variability Across Key Markets
7.4 Formulation Challenges: Stability, Penetration & Bioavailability
7.5 Greenwashing Scrutiny & Sustainability Claims Complexity
8. Key Players in Global Cosmetic Peptides - Competitive Landscape and SWOT Analysis
8.1 Croda International (Beauty Actives) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.2 Lubrizol (Lipotec Active Ingredients) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.3 Clariant (Lucas Meyer Cosmetics) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.4 Evonik (Care Solutions - Cosmetic Actives) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.5 Givaudan (Active Beauty) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.6 BASF SE (Personal Care Ingredients) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.7 Symrise AG (Cosmetic Actives) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.8 DSM-Firmenich (Skin Bioactives) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.9 GL Biochem (Shanghai) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
8.10 Spec-Chem Industry (China) — Revenue, Volume and Gross Margin (2020-2025E) + SWOT Analysis
9. Competitive Landscape of Key Players in the Global Cosmetic Peptides Market
9.1 Revenue Comparison & Market Share 2024-2031 (USD Million)
9.2 Revenue Growth Analysis: Winners and Laggards
9.3 Product Coverage Matrix
9.4 Geographic Coverage Matrix
9.5 Strategic Capability Benchmarking
9.6 Head-to-Head: Croda Beauty Actives vs. Lubrizol Lipotec
9.7 M&A Activity, Partnerships and Strategic Moves
9.8 Strategic Positioning Framework
9.9 Competitive Summary Scorecard
10. Porter's Five Forces Analysis of Global Cosmetic Peptides Market
10.1 Bargaining Power of Suppliers: Low-Medium
10.2 Bargaining Power of Buyers: Medium-High
10.3 Threat of New Entrants: Low-Medium
10.4 Threat of Substitution: Medium
10.5 Intensity of Competitive Rivalry: High
11. PESTLE Analysis of Global Cosmetic Peptides Market
11.1 Political (P) · 11.2 Economic (E) · 11.3 Social (S) · 11.4 Technological (T) · 11.5 Legal (L) · 11.6 Environmental (E)
12. SWOT Analysis of Global Cosmetic Peptides Market
13. Future Trends in Global Cosmetic Peptides Market
Suite Bonus Deliverables
Executive Presentation A cross-market PowerPoint presentation synthesising the key findings, market sizes, growth rates, segment leaders, regional dynamics, and strategic linkages across all three reports into a single executive-ready deck.
Cross-Market Summary Document A structured summary document explaining how the three peptide markets interconnect across the value chain — from raw API synthesis through therapeutic drug manufacturing to cosmetic active ingredients — with a publisher's methodology note explaining how figures across the three reports relate to one another.
Interactive Infographic A high-impact visual infographic presenting the key headline data from all three markets in a format designed for executive briefings, investor presentations, and stakeholder communication.

Companies Mentioned

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Novartis AG
  • Ipsen SA
  • AbbVie Inc.
  • Teva Pharmaceutical Industries
  • AstraZeneca plc
  • Ferring Pharmaceuticals
  • Pfizer Inc.
  • Amgen Inc.
  • Bachem (Julius Bachem AG)
  • PolyPeptide Group
  • CordenPharma International
  • WuXi STA (WuXi AppTec Peptide)
  • Hybio Pharmaceutical
  • AmbioPharm Inc.
  • ScinoPharm Taiwan
  • Almac Group
  • Piramal Pharma Solutions
  • CPC Scientific Inc.
  • GL Biochem (Shanghai) Ltd.
  • Croda International
  • Lubrizol (Lipotec Active Ingredients)
  • Clariant (Lucas Meyer Cosmetics)
  • Evonik
  • Givaudan
  • BASF SE
  • Symrise AG
  • DSM-Firmenich
  • Spec-Chem Industry (China)

Related Reports

Peptide Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Peptide Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 187 Pages
  • Global
From
Global Peptide API Market Strategic Research Report 2026-2031 - Product Image

Global Peptide API Market Strategic Research Report 2026-2031

  • Report
  • 201 Pages
  • Global
From
Peptide Therapeutics Market - Global Forecast to 2036 - Product Image

Peptide Therapeutics Market - Global Forecast to 2036

  • Report
  • 310 Pages
  • Global
From
Peptide Synthesis Market (3rd Edition) by Type of API, Type of Peptide Synthesis Method, Type of Chemical Synthesis Method, Scale of Operation, Company Size, Geographical Regions - Trends and Forecast Till 2035 - Product Image

Peptide Synthesis Market (3rd Edition) by Type of API, Type of Peptide Synthesis Method, Type of Chemical Synthesis Method, Scale of Operation, Company Size, Geographical Regions - Trends and Forecast Till 2035

  • Report
  • 390 Pages
  • Global
From
Pharmaceutical CDMO 2.0 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pharmaceutical CDMO 2.0 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.